Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

1.3K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.3K
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

596
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
596
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

361
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
361
Inflammatory Response I: Vascular and Cellular01:30

Inflammatory Response I: Vascular and Cellular

17.6K
The inflammatory response is the body's defense against infection, injury, or irritation from bacteria, trauma, toxins, or heat. Inflammation helps locate and destroy pathogens and remove damaged tissue elements to heal the body. During this initial phase, fluid, blood products, and nutrients migrate to the injured area, resulting in redness, heat, swelling, ache, and loss of function. Moreover, signs of systemic inflammation include fever, increased WBC count, malaise, anorexia, nausea,...
17.6K
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

76
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
76
Inflammatory Response01:28

Inflammatory Response

17.7K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
17.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of fourteen rule-out strategies for acute myocardial infarction.

International journal of cardiology·2018
Same author

Daytime variation of perioperative myocardial injury in non-cardiac surgery and effect on outcome.

Heart (British Cardiac Society)·2018
Same author

Variations on classification of main types of myocardial infarction: a systematic review and outcome meta-analysis.

Clinical research in cardiology : official journal of the German Cardiac Society·2018
Same author

Rhabdomyolysis: A Noncardiac Source of Increased Circulating Concentrations of Cardiac Troponin T?

Journal of the American College of Cardiology·2018
Same author

Reply: Hospital Charges Associated With Inpatient Troponin Testing.

Journal of the American College of Cardiology·2018
Same author

Inflammatory Biomarkers and Clinical Judgment in the Emergency Diagnosis of Urgent Abdominal Pain.

Clinical chemistry·2018
Same journal

Silent cerebral infarction after proximal thoracic aortic surgery under deep hypothermic circulatory arrest: an exploratory prospective DW-MRI study.

BMC cardiovascular disorders·2026
Same journal

Identifying risk individuals for heart failure diagnosis within two years in the adult population in southern Sweden using gender, age, multimorbidity level, and socioeconomic status.

BMC cardiovascular disorders·2026
Same journal

Combined associations of the metabolic score for insulin resistance and estimated glucose disposal rate with cardio-renal-metabolic multimorbidity: evidence from two large population studies.

BMC cardiovascular disorders·2026
Same journal

Elevated plasma TMAO levels associated with all-cause mortality in CAD patients in South China.

BMC cardiovascular disorders·2026
Same journal

Balloon aortic valvuloplasty for critical aortic stenosis in neonates and infants: early outcomes from a single-center cohort.

BMC cardiovascular disorders·2026
Same journal

Association between glucose-to-platelet ratio and all-cause mortality in critically ill patients with acute myocardial infarction: a retrospective cohort study.

BMC cardiovascular disorders·2026
See all related articles

Related Experiment Video

Updated: Mar 9, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K

Ticagrelor induced systemic inflammatory response syndrome.

Philipp Krisai1,2, Manuel Haschke3, Peter T Buser4

  • 1Department of Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland. philipp.krisai@usb.ch.

BMC Cardiovascular Disorders
|January 7, 2017
PubMed
Summary
This summary is machine-generated.

Ticagrelor, an antiplatelet medication, may cause Systemic Inflammatory Response Syndrome (SIRS). This case report highlights a potential adverse drug reaction to ticagrelor, prompting clinical awareness for early diagnosis and management.

Keywords:
Adverse drug reactionCase reportSIRSTicagrelor

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.9K

Related Experiment Videos

Last Updated: Mar 9, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.9K

Area of Science:

  • Pharmacology
  • Clinical Medicine
  • Critical Care Medicine

Background:

  • Ticagrelor is a P2Y12 receptor antagonist used to prevent thrombotic events.
  • The adenosine-mediated effects of ticagrelor, particularly on inflammation, are not fully understood.
  • Systemic Inflammatory Response Syndrome (SIRS) has not been previously associated with ticagrelor use.

Observation:

  • An 84-year-old patient developed SIRS after starting ticagrelor post-drug-eluting stent implantation.
  • Extensive investigations for other SIRS causes were negative.
  • Discontinuation of ticagrelor led to rapid resolution of SIRS symptoms.

Findings:

  • Ticagrelor was identified as the likely cause of SIRS in this patient.
  • This represents a novel adverse drug reaction associated with ticagrelor.
  • The case underscores the complexity of ticagrelor's interaction with inflammatory pathways.

Implications:

  • Clinicians should consider ticagrelor as a potential cause of SIRS.
  • Increased awareness of this adverse reaction is crucial due to ticagrelor's widespread use.
  • Prompt recognition and discontinuation of ticagrelor may be vital for managing SIRS in susceptible patients.